For research use only. Not for use in humans.

Farletuzumab (Anti-FOLR1)

Synonyms: FBP, Folbp1

Farletuzumab (Anti-FOLR1) is a humanized monoclonal antibody with high affinity for FRα. It is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. MW: 144.12 KD

Farletuzumab (Anti-FOLR1)

Quality Control

Batch: A249201 Purity: 99% Protein concentration: 19.19mg/ml Endotoxin Level: <1EU/mg
99

Specificity

Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Farletuzumab (Anti-FOLR1) is a humanized monoclonal antibody with high affinity for FRα. It is a potent folate receptor-alpha (FRα) inhibitor. Farletuzumab possesses growth-inhibitory functions on cells overexpressing FRα. Farletuzumab can be used in research of cancer. MW: 144.12 KD

Product Details

CAS No. 896723-44-7
Molecular Weight 144.12 kDa
Isotype Human IgG1
Source CHO
Purification AKTA
Sterility 0.2 μM filtered
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Storage
(From the date of receipt)
Store the undiluted solution at -20°C in the dark to avoid freeze-thaw cycles.

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT04300556 RECRUITING Drug: Farletuzumab ecteribulin|Drug: Prednisone|Drug: Predni Solid Tumor Eisai Inc. 2020-08-06 PHASE1; PHASE2
NCT05577715 TERMINATED Drug: MORAb-202 Carcinoma, Non-Small-Cell Lung Bristol-Myers Squibb 2022-11-14 PHASE2
NCT05613088 COMPLETED Drug: MORAb-202|Drug: Paclitaxel|Drug: Pegylated Liposomal D Neoplasms, Ovarian Bristol-Myers Squibb 2023-02-01 PHASE2
NCT03386942 COMPLETED Drug: Farletuzumab Ecteribulin Solid Tumors Eisai Inc. 2017-11-28 PHASE1
NCT02289950 COMPLETED Drug: Farletuzumab|Drug: Placebo Platinum-Sensitive Ovarian Cancer in First Relapse Eisai Inc. 2015-03-19 PHASE2
NCT01203618 WITHDRAWN Drug: Farletuzumab Resectable, Non-functioning Pituitary Adenoma Morphotek 2011-02 PHASE2

(data from https://clinicaltrials.gov, updated on 2026-06-04)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.